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Objective: Peroxisome proliferator activated receptor a (PPARa) agonists are used in clinical practice as lipid-
lowering drugs and are also known to exert anti-inﬂammatory effects on various tissues. We hypothesized
that PPARa activation leads to anti-inﬂammatory and anti-destructive effects in human OA cartilage.
Methods: Cartilage explants obtained from six OA patients were cultured for 48 h with 10 ng/ml inter-
leukin (IL)1b as a pro-inﬂammatory stimulus. 100 mM Wy-14643, a potent and selective PPARa agonist,
was added to the cultures and gene expression of matrix metalloproteinase (MMP)1, MMP3, MMP13,
collagen type II (COL2A1), aggrecan and PPARa in cartilage explants and the release of glycosamino-
glycans (GAGs), nitric oxide (NO) and prostaglandin E2 (PGE2) in the culture media were analyzed and
compared to the control without Wy-14643.
Results: Addition of Wy-14643 decreased mRNA expression of MMP1, MMP3 and MMP13 in cartilage
explants that responded to IL1b,whereasWy-14643didnot affect geneexpressionofCOL2A1andaggrecan.
Wy-14643 also decreased secretion of inﬂammatorymarkerNO in the culturemediumof cartilage explants
responding to IL1b. Wy-14643 inhibited the release of GAGs by cartilage explants in culture media.
Conclusion: PPARa agonist Wy-14643 inhibited the inﬂammatory and destructive responses in human OA
cartilage explants and did not have an effect on COL2A1 or aggrecan mRNA expression. These effects of
PPARa agonists on osteoarthritic cartilage warrant further investigation of these drugs as a potential
therapeutic strategy for osteoarthritis (OA).
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Loss of structure of articular cartilage is an important character-
istic of osteoarthritis (OA). Inﬂammatory responses in the joint,
leading to the production of cartilage matrix enzymes and pro-
inﬂammatory cytokines, contribute to the disruption of the balance
between anabolismand catabolism in cartilage1. To date, nodrugs are
able to prevent the initiation and progression of OA2. Peroxisome
proliferator activated receptor (PPAR)a is a class I nuclear receptor
belonging to the superfamily of ligand-dependent transcription
factors regulating the transcription of target genes by binding reti-
noid X receptor. In addition, PPARa modulates gene transcription in: G.J.V.M. Van Osch, Depart-
y Medical Centre Rotterdam,
. Van Osch).
s Research Society International. Pa DNA binding-independent manner3,4. Natural ligands of PPARa are
polyunsaturated fatty acids or arachidonic metabolites (prostaglan-
dins and leukotrienes). Synthetic ligands of PPARa areWy-14643 and
ﬁbrates, including gemﬁbrozil, cloﬁbrate, fenoﬁbrate and
bezaﬁbrate5e7. Fibrates are clinically used as drugs that lower plasma
triglyceride and cholesterol levels through the induction of b- andu-
oxidative pathways, which neutralize and degrade fatty acids8. In
addition, anti-inﬂammatory effects of PPARa activation have been
described9. These anti-inﬂammatory effects mainly depend on the
inhibition of the nuclear translocation of nuclear factor-kB (NF-kB),
which plays an important role in the regulation of inﬂammatory
responses10.
PPARa is present in a broad range of cells such as hepatocytes,
myocardiocytes, skeletal myocytes, endothelial cells, and also in
chondrocytes11e15. PPARa activation inhibits the production of
metalloproteinases in rabbit articular chondrocytes cultured in
monolayer and stimulated with interleukin (IL)1b by potentiating
the IL1b induced upregulation of IL1 receptor antagonist (IL1ra)16.ublished by Elsevier Ltd. All rights reserved.
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conﬁrmed by Poleni et al.17. They also showed that PPARa might
decrease proteoglycan and collagen type II (COL2A1) synthesis in
rat chondrocytes embedded in alginate beads18. The effect of PPARa
activation on inﬂammatory and destructive responses in human OA
cartilage explants has not yet been established. The aim of this
study is to investigate whether PPARa stimulation can reduce
inﬂammatory responses in human OA cartilage and to further
explore the inﬂuence of this stimulation on anabolic factors
COL2A1 and aggrecan. More evidence for a beneﬁcial role of PPARa
stimulation on cartilage homeostasis is crucial in order to clarify the
potential of drugs such as ﬁbrates as a therapeutic strategy for OA.
In this study, we investigated the effect ofWy-14643 on anabolic,
catabolic and inﬂammatory markers in osteoarthritic cartilage
explants. COL2A1 and aggrecan are important molecules in the
extracellular matrix, and matrix metalloproteinase (MMP)1 (colla-
genase 1), MMP3 (stromelysin 1), MMP13 (collagenase 3) are
involved in matrix degradation in OA19,20. To assess the anti-
inﬂammatory properties of Wy-14643, we analyzed nitric oxide
(NO) and prostaglandin E2 (PGE2) production by the cartilage
explants since these are known mediators of inﬂammation,
destruction and pain21e23. As mentioned before, NF-kB is a target of
PPARa agonists. Therefore, we also investigated whether PPARa
activation inhibits the nuclear translocation of NF-kB in human OA
chondrocytes.
Materials & methods
Preparation of human cartilage explants and human chondrocytes
Cartilage was obtained as anonymous waste material from six
human OA patients who underwent total knee arthroplasty. The
patients had the right to consent as stated by the guidelines of the
Dutch Federation of Biomedical Scientiﬁc Societies (www.federa.
org). This method was approved by the Local Ethical Committee
(number MEC 2004-322). Explants with diameter of 6 mm were
prepared using biopsy punches. Nine explants were consolidated in
3 ml Dulbecco’s modiﬁed Eagle’s medium (DMEM) high glucose
(GibcoBRL, Gaithersburg, MD, USA), supplemented with 2% fetal
calf serum (Lonza, Basel, Switzerland), 50 mg/ml gentamycin (Gib-
coBRL, Grand Island, NY, USA) and 1.5 mg/ml fungizone (GibcoBRL,
Grand Island, NY, USA) for 24 h in six well plates.
Study design
After pre-culture theexplantswerewashed inphosphate buffered
saline and the culture mediumwas replaced by DMEM high glucose
with Insulin-Transferrin-Selenium (Becton Dickinson Biosciences,
Erembodegem, Belgium). Explants were cultured simultaneously
with or without 10 ng/ml IL1b (Peprotech Rocky Hill, NJ, USA)
as a pro-inﬂammatory stimulus and with or without 10 or 100 mM
Wy-14643 (Cayman Chemical, Ann Arbor, MI, USA), a potent and
selective PPARa agonist17. Because Wy-14643 was dissolved in
Dimethyl-Sulfoxide (DMSO; Sigma, St. Louis, MO, USA), DMSO was
also added to the control and 10 mMconditions in order to correct for
the concentrationpresent in 100 mMWy-14643. After 48 h of culture,
cartilage explants and culture media were snap frozen in liquid
nitrogen and stored in 80C until further use.
RNA extraction and real-time polymerase chain reaction (PCR)
For each of the six donors, three samples were analyzed per
experimental condition. Each sample consisted of three explants that
were homogenized with a Mikro-Dismembrator (Braun Biotech
International GmbH,Melsungen, Germany) and suspended in 1.8 ml/100 mg tissue RNA-Bee (Bioconnect, Huissen, The Netherlands), in
order to obtain sufﬁcient RNA. RNA-bee suspended RNA was
precipitated with 0.2 ml chloroform. RNA was puriﬁed using an
RNeasyMicro Kit (Qiagen, Hilden, Germany). 500 ng of total RNAwas
reverse-transcribed into cDNA using RevertAid First Strand cDNA
synthesis Kit (MBI Fermentas, St. Leon-rot, Germany). By means of
PrimerExpress 2.0 software (Applied Biosystems, Foster City, CA,
USA), forward and reverseprimers for the real-time (RT)-PCRreaction
were designed to meet TaqMan requirements, and to bind the sepa-
rate exons to avoid ampliﬁcation of genomic DNA. The designed
primer sequences were run against a genome-wide database Basic
Local Alignment Search Tool (BLASTN) to ensure gene speciﬁcity of
the primers and probes. The following forward and reverse oligo-
nucleotides were used: MMP1 (Fw: CTCAATTTCACTTCTGTTTTCTG
Rv: CATCTCTGTCGGCAAATTCGT probe: CACAACTGCCAAATGGGCTT-
GAAGC; GenBank accession no. NM_002421), MMP3
(Fw: TTTTGGCCATCTCTTCCTTCA Rv: TGTGGATGCCTCTTGGGTATC
probe: AACTTCATATGCGGCATCCACGCC; GenBank accession no.
NM_002422), MMP13 (Fw: AAGGAGCATGGCGACTTCT Rv:
TGGCCCAGGAGGAAAAGC probe: CCCTCTGGCCTGCGGCTCA;
GenBank accession no. NM_002427), COL2A1; Fw: GGCAA-
TAGCAGGTTCACGTACA Rv: CGATAACAGTCTTGCCCCACTT probe:
CCGGTATGTTTCGTGCAGCCATCCT; GenBank accession no.
NM_033150, aggrecan (Fw: TCGAGGACAGCGAGGCC Rv:
TCGAGGGTGTAGCGTGTAGAGA probe: ATGGAACACGATGCCTTTCA-
CCACGA; GenBank accession no. NM_001135) and PPARa (Fw:
GACGTGCTTCCTGCTTCATAGA Rv: CCACCATCGCGACCAGAT; GenBank
accession no. NM_005036). TaqMan Universal PCR Master Mix (ABI,
Branchburg, NJ, USA) or qPCR Mastermix Plus for SYBRGreen I
(Eurogentec, Nederland B.V., Maastricht, The Netherlands) was used
to perform real-time (RT)-PCR in 20 ml reactions according to the
manufacturer’s guidelines and using an ABI PRISM 7000 with SDS
software, version 1.2.3. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; fw: ATGGGGAAGGTGAAGGTCG Rv: TAAAAGCAGCCCTGGT-
GACC Probe: CGCCCAATACGACCAAATCCGTTGAC GenBank accession
no. NM_002046.3) was compared with two other housekeeping
genes (data not shown) and was found to have good stability
throughout the conditions and samples. Relative gene expressionwas
calculated by means of the 2DCT formula.
Assays on culture media for viability, NO, PGE2 and
glycosaminoglycans (GAGs)
The pooled culture media of three samples per condition for each
patient (N¼ 6patients)were harvested to test the effect ofWy-14643
on the viability of chondrocytes using the Cytotoxicity Detection Kit
(Roche Diagnostics, IN, USA) in accordance with the manufacturer’s
instructions to determine the presence of lactate dehydrogenase
(LDH) in culture media. The amount of NO was measured using the
spectrophotometric method based on the Griess reaction (Sigma,
St. Louis, MO, USA). Absorbance was measured at 540 nm. PGE2
content of the culture media was determined using the PGE2 Assay
(RnD systems, Minneapolis, MN, USA) according to manufacturer’s
instructions at absorbance of 450 nm. The release of GAGs from
cartilage explants into the culture medium was analyzed with the
dimethylmethylene blue (DMB) assay24. Themetachromatic reaction
with DMB was monitored with a spectrophotometer and a ratio
A530:A590 was used to determine the GAG amount with chondroitin
sulfate C (Sigma) as standard. Analyses were performed in duplicate
and the averages of these results were used for statistical analysis.
NF-kB nuclear translocation in humane chondrocytes
Chondrocytes were isolated by pronase (2 mg/ml, Sigma,
St. Louis, MO, USA) digestion for 1 h and a half, followed by
Fig. 1. Catabolic responses of cartilage explants after 48 h of culture with IL1b and
with(out) PPARa agonist Wy-14643. mRNA expression of (A) MMP 1, (B) MMP3 and
(C) MMP13. Gene expression is normalized to GAPDH. For each condition, N¼ 18
samples of cartilage, obtained from six donors. Averages of three samples are shown
for each donor. Each symbol represents one donor.
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nostics, Mannheim, Germany). The obtained chondrocytes were
seeded in a 48 wells plate with at a density of 20,000 cells/cm2 and
cultured in DMEMhigh glucose (GibcoBRL, Gaithersburg, MD, USA),
supplementedwith 10% fetal calf serum (Lonza, Basel, Switzerland),
50 mg/ml gentamycin (GibcoBRL, Grand Island, NY, USA) and 1.5 mg/
ml fungizone (GibcoBRL, Grand Island, NY, USA). Chondrocyteswere
precultured during 5e7 days. A preliminary experiment showed
that 1 h of IL1b incubationwas the optimal moment to evaluate NF-
kB activation (data not shown), as also previously reported25.
Chondrocytes were cultured for immunohistochemical detection of
NF-kB with or without 10 ng/ml IL1b and with or without 100 mM
Wy-14643 during 1 h. The cellswereﬁxated on the plate in formalin
4%. This was followed by incubation for 1 h with rabbit polyclonal
NF-kB p65 antibody (1/100 Ab-276; Signalway Antibody, Leusden,
The Netherlands). Finally, alkaline phosphatase labeled secondary
antibody was used in combination with a freshly prepared new
fuchsine substrate (Chroma, Kongen, Germany). An isotype IgG1
monoclonal antibody was used as negative control. If the nucleus
stained intensively red, cellswere deﬁned as positive for the nuclear
presence of NF-kB. The percentage of positive cells was determined
by two blinded and independent observers by scoring three times
100 cells/well.
Data analysis
Data were analyzed with PSAW statistics 18.0 (SPSS inc.
Chicago, IL, USA). A mixed linear model was used for the mRNA
expression data of in total 18 samples/condition, obtained from six
donors. For the pooled media analysis, we used a general linear
model. Since the error terms of these models are assumed to have
a normal distribution, we analyzed and conﬁrmed the normal
distribution of the residuals with the WilkeShapiro test. To
account for the differences in IL1b response between donors, the
statistical models for analyzing the effect of PPARa activationwere
adjusted for IL1b response. Therefore, the statistical analysis
indicates whether there is a signiﬁcant effect of PPARa activation
when considering the IL1b response. For the histological analysis
of NF-kB, a one-way analysis of variance (ANOVA) was performed
with a Bonferroni post hoc test, after testing the residuals for
normality with WilkeShapiro test. P< 0.05 was considered
statistically signiﬁcant.
Results
PPARa geneswere expressed in human OA cartilage. Stimulation
with IL1b did not have effect on PPARa gene expression (data not
shown).
In order to exclude detrimental effects of Wy-14643 on viability
of chondrocytes, we performed an LDH cytotoxicity assay on
cartilage explants cultured in 1 mM, 10 mM, 100 mM and 1000 mM of
Wy-14643. Only at the concentration of 1000 mM Wy-14643 LDH
concentration in the culture media was increased, indicating
a deleterious effect of Wy-14643 on chondrocyte viability. Viability
was preserved at concentrations of 1, 10 and 100 mM Wy-14643
(data not shown).
We observed no effects of 10 mM Wy-14643 on MMP, COL2A1,
aggrecan gene expression, GAG release, NO or PGE2 production and
therefore used the 100 mM concentration in our experiments.
We investigated the effect of Wy-14643 on degradationmarkers
in OA cartilage by gene expression analysis on MMP1, MMP3 and
MMP13 in OA cartilage samples stimulated with 10 ng/ml IL1b. The
addition of IL1b increased mRNA expression of MMP1 in samples of
ﬁve of six patients (P¼ 0.01), MMP3 in samples of ﬁve of six
patients (P¼ 0.08) and MMP13 in samples of all patients (P¼ 0.06).
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MMP13 (P< 0.001) was signiﬁcantly decreased by the addition of
Wy-14643 in the samples from patients that responded to the IL1b
stimulation by an increased expression of MMPs (Fig. 1). The
addition of IL1b decreased mRNA expression of COL2A1 in explants
of four of six patients (P¼ 0.02) and aggrecan in samples of ﬁve
of six patients (P¼ 0.02). This effect was not counteracted by
Wy-14643 (Fig. 2).
NO and PGE2 were analyzed in culture media of the cartilage
samples as markers of inﬂammation. IL1b increased the production
of NO in ﬁve of six patients (P¼ 0.10) and PGE2 production was
increased in ﬁve of six patients (P¼ 0.13). Wy-14643 decreased the
production of NO (P¼ 0.02) and PGE2 (P¼ 0.07) in samples that
responded to IL1b by an increased production of NO and PGE2
(Fig. 3).
IL1b increased GAG release in the culture media in three of six
patients (P¼ 0.23). Wy-14643 decreased the release of GAG, again
only in samples that responded to IL1b by an increased release of
GAGs (P¼ 0.005) (Fig. 3).
To investigate whether inhibition of the nuclear translocation of
NF-kB is an underlying mechanism contributing to the anti-
destructive and anti-inﬂammatory effects of PPARa activation, we
examined the location of NF-kB in human chondrocytes with
immunohistochemistry (Fig. 4). Here, we observed a 30% increase of
positive staining cells for nuclear NF-kB when adding 10 ng/ml IL1b
(P¼ 0.004). There was no effect of addingWy-14643 to the cells that
were not incubated with IL1b (P¼ 1.00), but we observed a decreaseFig. 2. Anabolic responses of cartilage explants after 48 h of culture with IL1b and
with(out) PPARa agonist Wy-14643. Relative mRNA expression of (A) COL2A1 and
(B) aggrecan. Gene expression is normalized to GAPDH. For each condition, N¼ 18
samples of cartilage, obtained from six donors. Averages of three samples are shown
for each donor. Each symbol represents one donor.
Fig. 3. Inﬂammatory and destructive responses of cartilage explants after 48 h of culture
with IL1b and with(out) PPARa agonist Wy-14643: supernatant was analyzed for (A) NO,
(B) PGE2 and (C) GAG release. For each condition and for each donor pooled culture
media were analyzed, resulting in N¼ 6 (donors). Each symbol represents one donor.of 34% (P¼ 0.001) by adding 100 mMWy-14643 to the IL1b incubated
cells.
Discussion
Addition of 100 mM PPARa agonist Wy-14643 decreased gene
expression of the catabolic markers MMP1, MMP3 andMMP13, and
decreased release of GAG and NO in human OA cartilage explants.
There was no effect of Wy-14643 on COL2A1 and aggrecan mRNA
expression. Interestingly, effects of PPARa activation were only
found in explants that responded to IL1b.
We show that PPARa agonists are able to counteract inﬂamma-
tory and destructive responses but only in IL1b responsive human
OA cartilage samples, as analyzed statistically with IL1b response as
a covariable. Our results are in concordance with a study of Francois
et al., that demonstrated that the addition of cloﬁbrate, another
PPARa agonist, counteracts IL1b inducedMMP1, 3 and 13 production
Fig. 4. Nuclear translocation of NF-kB in human chondrocytes cultured in monolayer. Immunolocalization (magniﬁcation 200 times) of (A) NF-kB in cells cultured in medium alone,
(B) with IL1b, (C) and with the combination of IL1b and 100 mM Wy-14643. N¼ 3 different cultures. P indicates a cell with positive nuclear staining, n: chondrocyte without
intranuclear presence of NF-kB. Figure 4D shows the percentages of cells with a positive nuclear staining for NF-kB in the different conditions. Bars indicate standard deviation.
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Their study demonstrated that the decrease in MMP1, 3 and 13 by
PPARa activation is due to the potentiation of IL1b stimulated
production of IL1ra. Without PPARa activation, IL1b modestly
induces the production of IL1ra, but the combination of IL1b and
PPARa leads to higher IL1ra levels that inhibit IL1b stimulation16. In
our study however, IL1ra mRNA expression (data not shown) did not
correlate with the outcome parameters. Therefore, other mecha-
nisms were considered for explaining the effect of PPARa activation.
NF-kB plays a central role in the generation of inﬂammatory and
destructive mediators in OA10,26. PPARa ligands have been described
to inhibit the nuclear translocation of NF-kB, in part by increasing the
expression of inhibitor kB-a (IkB-a)10. Under normal conditions,
NF-kB is present in the cytoplasm in an inactive form bound to IkB-a,
but inﬂammatory reactions induce the degradation of IkB-a and
allow NF-kB to translocate to the nucleus where it orchestrates the
transcription of cytokines, growth factors, chemokines, and survival
genes10. We conﬁrmed that a PPARa ligand partly inhibits the
nuclear translocation of NF-kB in human IL1b stimulated chon-
drocytes, although we cannot exclude that other inﬂammatory
pathways such as mitogen-activated protein kinase phosphorylation
(extracellular signal-regulated kinase, c-Jun NH2-terminal kinase,
p38) are involved10. Interestingly, in human colorectal epithelial
cells, PPARa ligands increased cyclo-oxygenase (COX2) gene
expression resulting in production of prostaglandins. This might be
due to the presence of a peroxisome proliferator response element
(PPRE) in the COX2 promotor region that binds to activated PPARa27.
In our study, COX2 gene expression and PGE2 protein expression are
not increased, and even decreased byWy-14643 in the explants that
responded to the IL1b stimulation. This indicates that, in IL1b stim-
ulated chondrocytes, the NF-kB dependant regulation of COX2overrules the promotion of COX2 gene expression by PPRE. In
contrast, the samples of patients that did not respond to IL1b may
lack NF-kB activation, leading to an overweight of the binding to the
PPRE and therefore showing no effect of Wy-14643 or even an
increase in gene expression of COX2 gene expression and PGE2
release in some patients.
Not all IL1b induced responses were counteracted by the PPARa
agonist. IL1b decreased gene expression of COL2A1 and aggrecan in
cartilage explants but this was not inﬂuenced byWy-14643. COL2A1
and aggrecanmRNA expression in the IL1b stimulated samples were
very low. To exclude the possibility that expression of these genes
could not be lowered by adding Wy-14643 because the expression
was already very low, we have added 100 mM Wy-14643 to unsti-
mulated samples and analyzed the mRNA expression of COL2A1 and
aggrecan. Here, 100 mM Wy-14643 also did not affect the gene
expression of COL2A1 and aggrecan (data not shown) indicating that
the main effect of PPARa activation is inhibiting inﬂammatory and
destructive, but not anabolic processes in cartilage. However, there
was a correlation between mRNA expression level (MMPs) and
protein release (NO, PGE2 and GAG). The samples of two patients
responded modestly to IL1b at both mRNA expression and protein
level, while four other patients had a great response at both levels,
indicating that gene expression data can be extrapolated to the
protein level.
In this study, we used human OA cartilage explants. Explants
resemble the in vivo situation since the extracellular matrix that
inﬂuences chondrocyte metabolism is still present. The explants
were stimulated with 10 ng/ml IL1b to mimic inﬂammatory
processes in an in vitromodel for OA28e30. However, not all cartilage
of patients responded to the IL1b stimulation. The difference in IL1b
response of the human cartilage explants to IL1b in our study are
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explants31. The large variability in responsemay be due to differences
in age, different levels in oxidative stress responsible for activating
NF-kB, and zonal differences in cartilage metabolism32e34. We
observed no effect of IL1b on PPARamRNA expression, in accordance
with the results of previous studies11,35.
Wy-14643was selected because it is a potent and selective PPARa
agonist. It exhibits 10 timesmore afﬁnity for PPARa (kd< 1 mM) than
does cloﬁbrate and fenoﬁbrate36e38 and is 50e500 times more
selective for PPARa than other subtypes of PPAR.Wy-14643 has been
used in concentrations higher than 100 mM before in other in vitro
studies11,18,39 and was demonstrated to remain a selective PPARa
agonist in chondrocytes at concentrations of 100 mM18 by Poleni et al.
In our study, 10 mMWy-14643 had no effect on any parameter in the
explants cultures, although effects of even lower concentrations of
less potent PPARa agonists have been observed on chondrocytes16.
The absence of an effect for 10 mMWy-14643 might be explained by
difﬁculties in penetration in the extracellular matrix of the explants,
since other studies were using chondrocyte cultures in monolayer.
Nonetheless, our study indicates that 100 mM Wy-14643 decreases
both destructive and inﬂammatory markers on cartilage explants,
conﬁrming the proof of principle that PPARa activation leads to
a decrease of inﬂammatory and destructive responses. Further
studies are needed to examine the effects of PPARa activation on
cartilagemetabolism and cartilage quality using longer term cultures
and to investigate whether PPARa ligands such as ﬁbrates, used in
clinical practice, can induce similar responses in cartilage as
observed in this study. N-3 polyunsaturated fatty acids are naturally
occurring agonists of PPARa and have been described to exert anti-
inﬂammatory properties on articular cartilage40. Since n-3 fatty
acids are PPARa ligands with low afﬁnity, we believe that high
concentrations or a high total ﬂux of fatty acids might induce the
anti-inﬂammatory effects of fatty acids in a joint through the acti-
vation of PPARa.
Conclusion
Drug research in OA has mainly focussed on cartilage, although
metabolic factors such as body mass index, plasma triglycerides,
cholesterol levels and subchondral vascular pathology might play
a role in the OA pathogenesis41e46. Therefore it would be interesting
to ﬁnd drugs capable of altering metabolic factors together with
inhibiting destructive or inﬂammatory responses in cartilage. PPARa
agonists may indirectly inﬂuence the OA disease process by the
prevention of subchondral vascular pathology, by lowering triglyc-
erides and cholesterol levels in plasma, and through their anti-
inﬂammatory effects on the blood vessels15,47,48. Our data provide
evidence that PPARa agonists, used as lipid-lowering drugs in clinical
practice (e.g., ﬁbrates), may improve cartilage metabolism in an
osteoarthritic joint by lowering MMP1, 13-gene expression, GAG
release and NO production. Therefore, we believe that the use of the
synthetic ligands of PPARa as a potential therapeutic strategy for OA
should be further explored.
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